Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Messenger RNA-based vaccines.

Steve Pascolo1

  • 1CureVac GmbH, Paul Ehrlich Strasse 15, 72076 Tübingen, Germany. sp@curevac.de

Expert Opinion on Biological Therapy
|July 23, 2004
PubMed
Summary
This summary is machine-generated.

Messenger RNA (mRNA) vaccines offer a versatile and safe alternative for vaccination. This review explores advances, advantages, and limitations of five mRNA vaccination methods.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NLRP1 inflammasome activation in skin equivalents reveals mechanistic insights into the roles of keratinocytes in psoriasis.

Cell death & disease·2026
Same author

Sequence simplification of antigen coding IVT mRNA allows accelerated synthetic DNA template generation and epitope immunogenicity validation.

Molecular therapy. Nucleic acids·2025
Same author

Adoptive cell therapy with macrophage-drug conjugates facilitates cytotoxic drug transfer and immune activation in glioblastoma models.

Science translational medicine·2025
Same author

Development of Thermostable and Immunogenic Block Copolymer Nanoparticles (BNPs) for mRNA Delivery.

Biomacromolecules·2025
Same author

LL37 complexed to double-stranded RNA induces RIG-I-like receptor signalling and Gasdermin E activation facilitating IL-36γ release from keratinocytes.

Cell death & disease·2025
Same author

Inflammatory cytokines mediate the induction of and awakening from metastatic dormancy.

Cell reports·2025
Same journal

Biologic modulation of ineffective erythropoiesis in thalassemia: mechanisms, clinical practice, and future targets.

Expert opinion on biological therapy·2026
Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026
Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026
Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026
Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026
Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026
See all related articles

Area of Science:

  • Molecular Biology
  • Immunology
  • Biochemistry

Background:

  • Ribonucleic acid (RNA) performs essential life functions, including genetic information transfer and enzymatic activity.
  • Recent scientific advancements have positioned RNA, particularly messenger RNA (mRNA), as a key focus in molecular medicine.
  • mRNA presents a promising alternative to traditional protein-, virus-, and DNA-based therapies for vaccination.

Purpose of the Study:

  • To review significant advancements in mRNA-based vaccination technologies.
  • To present the advantages and limitations of five distinct mRNA vaccination approaches.
  • To discuss the industrial, financial, and regulatory landscape of mRNA vaccines.

Main Methods:

  • Literature review of scientific breakthroughs in mRNA technology.

Related Experiment Videos

  • Analysis of five different mRNA-based vaccination strategies.
  • Examination of industrial, financial, and regulatory factors influencing mRNA vaccine development.

    • Main Results:

    • mRNA vaccines demonstrate versatility and safety as a vaccination platform.
    • Five distinct mRNA vaccination methods exhibit unique advantages and limitations.
    • Significant progress has been made in developing mRNA as a therapeutic and prophylactic agent.

    Conclusions:

    • mRNA technology is revolutionizing vaccine development, offering a potent alternative to conventional methods.
    • Further research and development are crucial for optimizing mRNA-based vaccines for various diseases.
    • The integration of scientific, industrial, and financial aspects is key to the future of mRNA therapeutics.